Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
出版年份 2015 全文链接
标题
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
作者
关键词
Exenatide, Type 2 diabetes mellitus, Hyperglycemia, Weight response, Cardiovascular risk, Biomarkers
出版物
Cardiovascular Diabetology
Volume 14, Issue 1, Pages 12
出版商
Springer Nature
发表日期
2015-02-03
DOI
10.1186/s12933-014-0171-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Overweight in Early Adulthood, Adult Weight Change, and Risk of Type 2 Diabetes, Cardiovascular Diseases, and Certain Cancers in Men: a Cohort Study
- (2014) Renée de Mutsert et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production
- (2014) Eszter Sélley et al. Cardiovascular Diabetology
- Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3
- (2014) Yasuo M Tsutsumi et al. Cardiovascular Diabetology
- Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis
- (2014) Jinmi Lee et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Impact of body mass index, metabolic health and weight change on incident diabetes in a Korean population
- (2014) Hyun-Suk Jung et al. Obesity
- Heart Disease and Stroke Statistics—2014 Update
- (2013) Alan S. Go et al. CIRCULATION
- Standards of Medical Care in Diabetes--2014
- (2013) DIABETES CARE
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
- (2012) M. Davies et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme
- (2012) K. Niswender et al. DIABETES OBESITY & METABOLISM
- Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
- (2012) Baptist Gallwitz et al. LANCET
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
- (2012) Linong Ji et al. Journal of Diabetes Investigation
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
- (2010) Caroline M. Apovian et al. AMERICAN JOURNAL OF MEDICINE
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started